Logo image of SNOA

SONOMA PHARMACEUTICALS INC (SNOA) Stock Fundamental Analysis

USA - NASDAQ:SNOA - US83558L3033 - Common Stock

3.94 USD
-0.1 (-2.48%)
Last: 9/29/2025, 8:07:54 PM
3.94 USD
0 (0%)
Pre-Market: 9/30/2025, 8:00:10 AM
Fundamental Rating

2

SNOA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SNOA have multiple concerns. SNOA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SNOA had negative earnings in the past year.
In the past year SNOA has reported a negative cash flow from operations.
SNOA had negative earnings in each of the past 5 years.
In the past 5 years SNOA always reported negative operating cash flow.
SNOA Yearly Net Income VS EBIT VS OCF VS FCFSNOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

1.2 Ratios

SNOA has a Return On Assets of -24.36%. This is comparable to the rest of the industry: SNOA outperforms 57.14% of its industry peers.
SNOA's Return On Equity of -87.65% is in line compared to the rest of the industry. SNOA outperforms 44.39% of its industry peers.
Industry RankSector Rank
ROA -24.36%
ROE -87.65%
ROIC N/A
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
SNOA Yearly ROA, ROE, ROICSNOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

Looking at the Gross Margin, with a value of 37.71%, SNOA is in the better half of the industry, outperforming 60.20% of the companies in the same industry.
SNOA's Gross Margin has declined in the last couple of years.
SNOA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
SNOA Yearly Profit, Operating, Gross MarginsSNOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNOA has been increased compared to 1 year ago.
Compared to 5 years ago, SNOA has less shares outstanding
The debt/assets ratio for SNOA has been reduced compared to a year ago.
SNOA Yearly Shares OutstandingSNOA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
SNOA Yearly Total Debt VS Total AssetsSNOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -17.85, we must say that SNOA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SNOA (-17.85) is worse than 79.08% of its industry peers.
SNOA has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
SNOA's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. SNOA outperforms 55.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -17.85
ROIC/WACCN/A
WACC9.8%
SNOA Yearly LT Debt VS Equity VS FCFSNOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 2.70 indicates that SNOA has no problem at all paying its short term obligations.
SNOA has a Current ratio (2.70) which is in line with its industry peers.
A Quick Ratio of 1.92 indicates that SNOA should not have too much problems paying its short term obligations.
SNOA has a Quick ratio (1.92) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.7
Quick Ratio 1.92
SNOA Yearly Current Assets VS Current LiabilitesSNOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

SNOA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.64%, which is quite impressive.
Looking at the last year, SNOA shows a quite strong growth in Revenue. The Revenue has grown by 17.44% in the last year.
SNOA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.44% yearly.
EPS 1Y (TTM)46.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%18.4%

3.2 Future

The Earnings Per Share is expected to grow by 15.06% on average over the next years. This is quite good.
The Revenue is expected to grow by 17.80% on average over the next years. This is quite good.
EPS Next Y-96.42%
EPS Next 2Y15.06%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y17.8%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SNOA Yearly Revenue VS EstimatesSNOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
SNOA Yearly EPS VS EstimatesSNOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2021 2024 2025 2026 2027 0 -500 -1K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNOA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNOA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNOA Price Earnings VS Forward Price EarningsSNOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNOA Per share dataSNOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

SNOA's earnings are expected to grow with 15.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.06%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SNOA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SONOMA PHARMACEUTICALS INC

NASDAQ:SNOA (9/29/2025, 8:07:54 PM)

Premarket: 3.94 0 (0%)

3.94

-0.1 (-2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners6.31%
Inst Owner Change192.67%
Ins Owners1.28%
Ins Owner Change0%
Market Cap6.46M
Analysts85.71
Price Target15.1 (283.25%)
Short Float %3.06%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.96%
Min Revenue beat(2)-17.11%
Max Revenue beat(2)-2.81%
Revenue beat(4)0
Avg Revenue beat(4)-11.43%
Min Revenue beat(4)-17.11%
Max Revenue beat(4)-2.81%
Revenue beat(8)0
Avg Revenue beat(8)-14.73%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.53%
EPS NY rev (1m)0%
EPS NY rev (3m)26.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.43
P/FCF N/A
P/OCF N/A
P/B 1.59
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)-2.46
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS9.09
BVpS2.47
TBVpS2.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.36%
ROE -87.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.71%
FCFM N/A
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
F-Score4
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.07%
Cap/Sales 1.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.7
Quick Ratio 1.92
Altman-Z -17.85
F-Score4
WACC9.8%
ROIC/WACCN/A
Cap/Depr(3y)91.77%
Cap/Depr(5y)85.45%
Cap/Sales(3y)0.91%
Cap/Sales(5y)0.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
EPS Next Y-96.42%
EPS Next 2Y15.06%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.44%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%18.4%
Revenue Next Year11.38%
Revenue Next 2Y17.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.39%
OCF growth 3YN/A
OCF growth 5YN/A